Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Levocetirizine and Fexofenadine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~Eighteen (18) healthy male volunteers, including at least 6 persons of Japanese origin, will be recruited for this study~Exclusion Criteria:~* None of the subjects will have taken oral antihistamines, antidepressants, antipsychotics or corticosteroids or applied topical antihistamines, corticosteroids or mast cell stabilizers to the skin for 2 weeks prior to testing.~* No subject shall perform physical exercise for 4 hours prior to the skin prick testing.~* Especially, Bronchial asthma, anaphylactic reactions in the history, use of beta-blockers, skin diseases in the test field are exclusion criteria.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo per os at time 0 hours + placebo per os at 12 hours.
- Levocetirizin (Type: ACTIVE_COMPARATOR): Levocetirizin 5mg at time 0 and placebo per os at 12 hours
- Fexofenadine (Type: ACTIVE_COMPARATOR): Fexofenadine 60mg per os at time 0 hours + fexofenadine 60mg per os at 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).